Comment on “Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis”
摘要
This commentary appraises Pieniążek et al.’s study on hematologic prognostic markers in sacituzumab govitecan–treated mTNBC, emphasizing residual confounding, absent Trop-2 data, limited modeling flexibility, and incomplete handling of missingness. Methodological refinement and integration of biological, longitudinal, and clinical variables are proposed to enhance prognostic accuracy and translational applicability.